OncoMatch/Clinical Trials/NCT04991870
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Is NCT04991870 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Cord Blood-derived Expanded Allogeneic Natural Killer Cells for recurrent gliosarcoma.
Treatment: Cord Blood-derived Expanded Allogeneic Natural Killer Cells — This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Allowed: IDH1 wild-type
recurrent IDH WT glioblastoma
Allowed: IDH1 mutation
recurrent IDHmutant grade 4 astrocytoma
Disease stage
Required: Stage GRADE 4 (World Health Organization)
Grade: 4 (World Health Organization)
World Health Organization grade 4 recurrent astrocytoma
Prior therapy
Must have received: radiation therapy
have received prior radiation and temozolomide therapy
Must have received: alkylating agent (temozolomide)
have received prior radiation and temozolomide therapy
Cannot have received: Gliadel (Gliadel)
Has received prior therapy with Gliadel
Cannot have received: VEGF inhibitor (bevacizumab)
Has received prior therapy with...bevacizumab
Cannot have received: interstitial brachytherapy
Has received prior interstitial brachytherapy
Cannot have received: implanted chemotherapy
Has received prior...implanted chemotherapy
Cannot have received: local injection or convection enhanced delivery
Has received prior...therapeutics delivered by local injection or convection enhanced delivery
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody within the last three months
Lab requirements
Blood counts
WBC ≥ 3 x 10^9/L, ANC ≥ 1.5 x 10^9/L, lymphocyte count ≥ 0.5 x 10^9/L, platelet count ≥ 100 x 10^9/L, Hgb ≥ 9 g/dL (in absence of blood transfusion)
Kidney function
creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for participant with creatinine levels > 1.5 x institutional ULN
Liver function
total bilirubin level ≤ 1.5 x ULN, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, INR ≤ 1.5
Adequate hematological function... Adequate hepatic function... Adequate renal function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify